Literature DB >> 11883863

The finding of a somaticdeletion in RET exon 15 clarified the sporadic nature of amedullary thyroid carcinoma suspected to be familial.

J Oriola1, I Halperin, F Rivera-Fillat, H Donis-Keller.   

Abstract

Medullary thyroid carcinoma (MTC) occurs both sporadically and in the autosomal dominantly inherited multiple endocrine neoplasia (MEN) type 2 syndromes. The distinction between both is important for future clinical management. We report a family initially described as a familial MTC by pentagastrin stimulation test and clinical outcome, in which we found a 12 bp deletion within the catalytic domain of the protooncogene RET in the index case tumor alone. Linkage study suggests that it is a sporadic MTC. Therefore, in view of these results, in kindred with just one MTC case, borderline pentagastrin test values must be carefully assessed. In addition, this and other mutations can help us to understand some features about domains that play an important role in the normal function of this tyrosine kinase receptor and involved in MTC.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11883863     DOI: 10.1007/BF03343957

Source DB:  PubMed          Journal:  J Endocrinol Invest        ISSN: 0391-4097            Impact factor:   4.256


  42 in total

1.  Unexpected high calcitonin concentrations after pentagastrin stimulation.

Authors:  B Kempter; M M Ritter
Journal:  Clin Chem       Date:  1991-03       Impact factor: 8.327

2.  Phosphotransferase sequence homology.

Authors:  S Brenner
Journal:  Nature       Date:  1987 Sep 3-9       Impact factor: 49.962

3.  Somatic in frame deletions not involving juxtamembranous cysteine residues strongly activate the RET proto-oncogene.

Authors:  I Ceccherini; B Pasini; F Pacini; M Gullo; I Bongarzone; C Romei; G Santamaria; I Matera; P Mondellini; L Scopsi; A Pinchera; M A Pierotti; G Romeo
Journal:  Oncogene       Date:  1997-05-29       Impact factor: 9.867

4.  Diagnosis of medullary carcinoma of the thyroid (MCT) by calcitonin assay using monoclonal antibodies: criteria for the pentagastrin stimulation test in hereditary MCT.

Authors:  D Guilloteau; R Perdrisot; C Calmettes; J L Baulieu; P Lecomte; G Kaphan; G Milhaud; J C Besnard; P Jallet; J C Bigorgne
Journal:  J Clin Endocrinol Metab       Date:  1990-10       Impact factor: 5.958

5.  RET proto-oncogene mutations in inherited and sporadic medullary thyroid cancer.

Authors:  J E Blaugrund; M M Johns; Y J Eby; D W Ball; S B Baylin; R H Hruban; D Sidransky
Journal:  Hum Mol Genet       Date:  1994-10       Impact factor: 6.150

6.  Age-associated C-cell hyperplasia in the human thyroid.

Authors:  W G Gibson; T C Peng; B P Croker
Journal:  Am J Pathol       Date:  1982-03       Impact factor: 4.307

Review 7.  Sporadic endocrine tumours and their relationship to the hereditary endocrine neoplasia syndromes.

Authors:  J W Koper; S W Lamberts
Journal:  Eur J Clin Invest       Date:  2000-06       Impact factor: 4.686

8.  Germ-line mutations of the RET proto-oncogene in multiple endocrine neoplasia type 2A.

Authors:  L M Mulligan; J B Kwok; C S Healey; M J Elsdon; C Eng; E Gardner; D R Love; S E Mole; J K Moore; L Papi
Journal:  Nature       Date:  1993-06-03       Impact factor: 49.962

9.  Identification of multiple endocrine neoplasia, type 2 gene carriers using linkage analysis and analysis of the RET proto-oncogene.

Authors:  M S Tsai; G A Ledger; S Khosla; H Gharib; S N Thibodeau
Journal:  J Clin Endocrinol Metab       Date:  1994-05       Impact factor: 5.958

10.  Pentagastrin stimulation test and early diagnosis of medullary thyroid carcinoma using an immunoradiometric assay of calcitonin: comparison with genetic screening in hereditary medullary thyroid carcinoma.

Authors:  N Barbot; C Calmettes; I Schuffenecker; J P Saint-André; B Franc; V Rohmer; P Jallet; J C Bigorgne
Journal:  J Clin Endocrinol Metab       Date:  1994-01       Impact factor: 5.958

View more
  2 in total

Review 1.  A comprehensive overview of the role of the RET proto-oncogene in thyroid carcinoma.

Authors:  Cristina Romei; Raffaele Ciampi; Rossella Elisei
Journal:  Nat Rev Endocrinol       Date:  2016-02-12       Impact factor: 43.330

Review 2.  Precision oncology for RET-related tumors.

Authors:  Antonella Verrienti; Giorgio Grani; Marialuisa Sponziello; Valeria Pecce; Giuseppe Damante; Cosimo Durante; Diego Russo; Sebastiano Filetti
Journal:  Front Oncol       Date:  2022-08-24       Impact factor: 5.738

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.